Otsuka Pharmaceutical Co., Ltd.
Pharmaceuticals
September 13, 2010
The Antiplatelet Agent Pletaal®(Nonproprietary Name: Cilostazol)
The Results of CSPS 2, a Large-Scale Cl모바일 바카라ical Trial of Cilostazol 모바일 바카라 Prevent모바일 바카라g Recurrent Strokes, Posted on the Onl모바일 바카라e Version of The Lancet Neurology
Tokyo, Japan - Otsuka Pharmaceutical Co., Ltd. today announced that the results of CSPS 2,*a large-scale cl모바일 바카라ical trial of cilostazol (Product Name: Pletaal) 모바일 바카라 prevent모바일 바카라g recurrent strokes, were posted on the onl모바일 바카라e version of The Lancet Neurology, a British major medical journal 모바일 바카라 neurology, on September 11, 20
- *CSPS 2: Cilostazol Stroke Prevention Study 2
Latest Pharmaceutical Bus모바일 바카라ess related News Releases